A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
← catalyst calendarNCT07758595 · readout ≤ 1,350 d
Sponsored by Denali Therapeutics Inc. (industry) · DNLI — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
178estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Apr 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer's Disease
- Healthy Participants
Interventions
- Drug: DNL921
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Incidence and severity of treatment-emergent averse events (TEAEs)
measured 46 days
Parts B and C: Incidence and severity of TEAEs in participants with AD
measured 242 days
Permalink · DNLI's whole pipeline · Catalyst calendar · Every registered study · What changed